Comparative Pharmacology
Head-to-head clinical analysis: BETAPACE versus BETAPACE AF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPACE versus BETAPACE AF.
BETAPACE vs BETAPACE AF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class III antiarrhythmic agent; prolongs cardiac action potential duration and refractory period by blocking potassium channels, primarily IKr.
Sotalol is a class III antiarrhythmic agent that also has non-cardioselective beta-adrenergic receptor blocking activity. It prolongs the cardiac action potential duration by blocking potassium channels (IKr), thereby prolonging the QT interval and refractory periods.
Oral: 80 mg twice daily; may increase up to 160 mg twice daily as needed.
80 mg orally twice daily. For atrial fibrillation/flutter, initiate at 80 mg twice daily; may increase after 2-3 days to 120 mg twice daily if needed. Maximum 120 mg twice daily.
None Documented
None Documented
12 hours (10-20 hours) in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment
Terminal elimination half-life: 12 hours (range 10–20 hours) in patients with normal renal function; prolonged in renal impairment (up to 42 hours in severe impairment).
Renal: >90% unchanged drug (sotalol) in urine; biliary/fecal: <10%
Primarily renal (unchanged drug and metabolites); approximately 40% excreted as unchanged sotalol in urine, with additional metabolites via fecal route (~10%). Biliary excretion minimal (<5%).
Category C
Category C
Beta-Blocker
Beta-Blocker